||Obatoclax, a Bcl-2 homology domain-3 mimetic, antagonize all antiapoptotic Bcl-2 family proteins (average IC50, 3 MolL), including Mcl-1 (IC50, 2.9 Mo
||Roscovitine is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM and shows little effect on CDK4/6
||Staurosporine is a prototypical potent ATP-competitive multikinase inhibitor with IC50 of 0.7, 7, 8.5, 6, 20 nM for PKC, PKA,PKG, p60v-src tyrosine pr
||U0126 ethanol is a highly selective inhibitor of MEK1/2 with IC50 of 70/60nM.
||SNS-032 is a potent inhibitor of cyclin-dependent kinases (CDKs)9, 2 and 7 (IC50 values are 4, 38 and 62 nM respectively).
||Selumetinib is a potent, highly selective MEK1 inhibitor with IC50 of 14 nM, also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to
||Ruxolitinib is the first potent, selective, JAK12 inhibitor to enter the clinic with IC50 of 3.3 nM2.8 nM, 130-fold selectivity for JAK12 versus JAK3
||Danusertib is a pyrrolo-pyrazole and small molecule Aurora kinases inhibitor with IC50 of 13 79 and 61 nM for Aurora A B and C respectively
||ABT-263 is a potent inhibitor of Bcl-xL Bcl-2 and Bcl-w with Ki ≤ 0.5nM, ≤1 nM and ≤1 nM in cell-free assays.
||Cabazitaxel is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel exerts it
||MK-4827 is an excellent PARP1 and PARP2 inhibitor with IC50 of 38 and 21 nM respectively
||Alisertib is a selective Aurora inhibitor with IC50 of 12 nM with 200-fold higher selectivity for Aurora A than Aurora B
||CHIR-99021 is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM, exhibiting > 500-fold selectivity for GSK-3 versus its closest homologs CDC2 and ERK2, a
||Romidepsin is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM, respectively.
||SCH772984 is a specific inhibitor of ERK12 with IC50 of 4 nM and 1 nM respectively
||Alpelisib is a potent and selective PI3Kα inhibitor with IC50 of 5 nM, liitle or no effect on PI3Kβ/γ/δ.
||AZD5363 is a potent pan-AKT kinase inhibitor with IC50 of 3, 7 and 7 nM for Akt1,Akt2 and Akt3, respectively.
||MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM, respectively, showing no inhibitory activities against 250 oth
||Ulixertinib is a potent and reversible ERK1ERK2 inhibitor with IC50 of 0.3 nM for ERK2.
||KU-60019 is an improved analogue of KU-55933 with IC50 of 63 nM for ATM
||BMN-673 is a PARP12 inhibitor with IC50 of 0.57 nM for PARP1.
||GSK2606414 is an orally available potent and selective PERK inhibitor with an IC50 of 04 nM
||GSK343 is a potent and selective EZH2 inhibitor with IC50 of 4 nM showing 60 fold selectivity against EZH1 and 1000 fold selectivity against other hi
||Z-VADOMe-FMK is a cell-permeable irreversible broad-spectrum caspase inhibitor blocks all features of apoptosis
||ARRY-162 is a potent inhibitor of MEK12 with IC50 of 12 nM in a cell-free assay.
||BGJ-398 is a selective, pan-specific FGFR inhibitor with IC50 of 0.9, 1.4, and 1 nM for FGFR1, FGFR2, and FGFR3, respectively and > 40-fold selective
||CP-673451 is a selective inhibitor of PDGFR with IC50 of 10 nM1 nM in cell-free assays exhibits 450-fold selectivity over other angiogenic receptors
||PND-1186 is a potent FAK inhibitor with IC50 of 1.5 nM.
||A-1210477 is a potent and selective inhibitor of MCL-1 and weakly binds to BCL-2 and BCL-XL with Ki of 045 nM 132 nM and 660 nM respectively
||KU-55933 is a potent ATM inhibitor with an IC50 and Ki of 13 and 22 nM respectively and highly selective for ATM as compared to DNA-PK PI3KPI4K ATR an
||CH5183284 is a selective and orally available FGFR inhibitor with IC50 of 9.3 nM, 7.6 nM, 22 nM, and 290 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respec
||Defactinib is a potent FAK phosphorylation inhibitor and overcomes YB-1mediated paclitaxel resistance by an AKT-dependent pathway.
||DMH-1 is a potent and selective BMP inhibitor with IC50s of 27107.9 5 nM for ALK123 respectively and inactive on ALK5, BMPR2, AMPK and VEGFR2.
||LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50s of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β respectively.
||SIS3 is an inhibitor of Smad3 and can inhibit TGF-β and activin signaling without affecting other pathways.
||ABT-737 is a BH3 mimetic inhibitor of Bcl-xL Bcl-2 and Bcl-w with EC50 of 787 nM 303 nM and 1978 nM respectively showing no inhibition observed agains
||PF-573228 is a potent and selective FAK inhibitor with IC50 of 4 nM for inhibiton of purified recombinant catalytic fragment of FAK and inhibits FAK p
||CPI 203 is a potent selective and cell permeable inhibitor of the bromodomain and extra terminal BET family protein BRD4 with an IC50 of 37 nM BRD4 -s
||Bafetinib is a potent and selective dual Bcr-AblLyn inhibitor with IC50 of 5.8 nM19 nM in cell-free assays, does not inhibit the phosphorylation of th
||I-BET 762 is an inhibitor for BET proteins with IC50 of 35 nM.
||PF-562271 besylate is a potent ATP-competitive reversible inhibitor of FAK with IC50 of 15 nM 10-fold less potent for Pyk2 than FAK and 100-fold sele
||BMS-777607 is a Met-related inhibitor for c-Met Axl Ron and Tyro3 with IC50 of 39 nM 11 nM 18 nM and 43 nM being 40-fold selective for Met-related tar
||Z-IETD-FMK is a specific Caspase-8 inhibitor
||Ki-20227 is a highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50 value of 2 nM, displaying 6 fold and 100 fold selectivity over VEGFR
||Ponatinib is a potent multi-target inhibitor of Abl PDGFR VEGFR2 FGFR1 and Src with IC50 of 037 nM 11 nM 15 nM 22 nM and 54 nM respectively
||PKC412 is a broad spectrum protein kinase inhibitor and inhibits conventional PKC isoforms (α, β, γ), PDFRβ, VEGFR2, Syk, PKCη, Flk-1, Flt3, Cdk1/B, P
||AT7519 is a pan-CDKs inhibitor with IC50 values of 47, 13, <10nM for CDK2/CyclinA, CDK5/p35 and CDK9/CyclinT, and modest activity against CDK1/CyclinB
||GDC-0994 is a selective inhibitor of ERK1/2 with IC50 value of 6.1 nM and 3.1 nM.
||2-methoxyestradiol is a natural metabolite of estrogen that is known to inhibit HIF-1 alpha with an IC50 of 0.71 ± 0.11 μM for the inhibition of BPAEC